A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

Inclusion Criteria * Age 18 years * Histologically confirmed diagnosis of HMB-45+ clear cell sarcoma which is unresectable and/or metastatic * HLA-A*02:01 positive * ECOG Performance Status of £ 2 at screening * At least one site of measurable disease on CT/MRI scan as defined by RECIST v 1.1 criteria. Baseline imaging must be performed within 28 days of Cycle 1 Day 1 of study. * Adequate organ function within 28 days of Day 1 of study defined as: * Absolute Neutrophil Count (ANC) ≥ 1.5 * Platelets ≥ 75 * ALT and AST ≤ 2.5 x institutional upper limit of normal (ULN) or ≤ 5.0 x institutional ULN if considered due to tumor * Alkaline phosphatase ≤ 2.5 x institutional ULN unless considered due to tumor * Serum bilirubin ≤ 1.5 x institutional ULN. NOTE: Patients with elevated bilirubin secondary to Gilbert's disease are eligible to participate in the…